Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Lundbeck is acquiring Prexton Therapeutics, which was spun off of Merck KGaA in 2012, for up to $1.1 billion. The centerpiece of the deal is foliglurax, a positive allosteric modulator of mGluR4 currently in Phase II studies in people with Parkinson’s disease. Foliglurax was developed by Merck and Domain Therapeutics, which in 2013 sold rights to the drug to Prexton. The compound addresses side effects of current Parkinson’s treatments, which alleviate symptoms by replacing dopamine but can cause involuntary muscle movements.
This article has been sent to the following recipient: